Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016

Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016
Published Jun 30, 2016
84 pages — Published Jun 30, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016, provides in depth analysis on Alpha-Synuclein (alphaSyn or SNCA) targeted pipeline therapeutics.

The report provides comprehensive information on the Alpha-Synuclein (alphaSyn or SNCA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Alpha-Synuclein (alphaSyn or SNCA)
- The report reviews Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha-Synuclein (alphaSyn or SNCA) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha-Synuclein (alphaSyn or SNCA)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading c

  
Source:
Document ID
GMDHC0262TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Alpha-Synuclein (alphaSyn or SNCA) Overview91
Therapeutics Development103
  Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Stage of Development101
  Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Therapy Area111
  Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Indication121
Alpha-Synuclein (alphaSyn or SNCA) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Companies153
Alpha-Synuclein (alphaSyn or SNCA) Products under Development by Universities/Institutes182
Alpha-Synuclein (alphaSyn or SNCA) Therapeutics Assessment206
  Assessment by Monotherapy/Combination Products201
  Assessment by Mechanism of Action211
  Assessment by Route of Administration222
  Assessment by Molecule Type242
Alpha-Synuclein (alphaSyn or SNCA) Companies Involved in Therapeutics Development2612
  AC Immune SA261
  AFFiRiS AG271
  BioArctic Neuroscience AB281
  Biogen, Inc.291
  NeuroPhage Pharmaceuticals, Inc.301
  Neuropore Therapies, Inc.311
  nLife Therapeutics, S.L.321
  Primary Peptides, Inc.331
  Prothena Corporation Plc341
  QR Pharma, Inc.351
  reMYND NV361
  Synovo GmbH371
Alpha-Synuclein (alphaSyn or SNCA) Drug Profiles3834
  BAN-0805 Drug Profile381
  BIIB-054 Drug Profile391
  CLR-01 Drug Profile401
  DPC-003 Drug Profile411
  Kenterin Drug Profile421
  Monoclonal Antibodies to Inhibit Tau, Amyloid Beta and Alpha-Synuclein for Neurodegenerative Diseases Drug Profile431
  NLFPD-1233 Drug Profile441
  NPT-001 Drug Profile452
  NPT-002 Drug Profile471
  NPT-005 Drug Profile481
  NPT-088 Drug Profile491
  NPT-133 Drug Profile501
  NPT-20011 Drug Profile511
  NPT-3G Drug Profile521
  PD-01 Drug Profile532
  PD-03 Drug Profile551
  PD-04 Drug Profile561
  Posiphen Drug Profile573
  PP-003 Drug Profile601
  PRX-002 Drug Profile612
  quinpramine Drug Profile631
  ReS-12S Drug Profile641
  ReS-9S Drug Profile651
  Small Molecule to Inhibit Alpha-Synuclein and Lcn2 for Parkinson's Disease Drug Profile661
  Small Molecule to Inhibit Alpha-Synuclein for Parkinson's Disease Drug Profile671
  Small Molecules to Inhibit Alpha-Synuclein for Parkinson's Disease Drug Profile681
  trehalose Drug Profile691
  Vaccine to Target Alpha-Synuclein for Neurodegenerative Disease Drug Profile701
  Vaccine to Target Alpha-Synuclein for Parkinson's Disease Drug Profile711
Alpha-Synuclein (alphaSyn or SNCA) Dormant Projects722
Alpha-Synuclein (alphaSyn or SNCA) Featured News &Press Releases749
  Mar 22, 2016: Neuropore Announces Successful Completion of Phase I with its Lead Compound NPT200-11741
  Aug 12, 2015: Neuropore Therapies Commences Phase 1 Clinical Trials741
  Jul 19, 2015: NeuroPhage's NPT088 Universally Targets Misfolded Proteins in Preclinical Studies Highlighted in Oral Session at the Alzheimer's Association International Conference741
  Jul 13, 2015: NeuroPhage to be Featured in Oral Session at the 2015 Alzheimer s Association International Conference751
  Jul 02, 2015: BIIB054 reached significant milestone751
  Jun 17, 2015: Prothena Presents Clinical Results Demonstrating Robust, Rapid Reduction in Levels of Free Serum Alpha-Synuclein of Up to 96% After Single Dose of PRX002, Novel Protein Immunotherapy for Parkinson's Disease751
  Jun 15, 2015: BioArctic Neuroscience Parkinson s disease program receives grant from VINNOVA761
  Jun 08, 2015: Prothena to Present Clinical Results From Its Phase 1 Single Ascending Dose Study of PRX002 at 19th International Congress of Parkinson's Disease and Movement Disorders771
  Apr 02, 2015: 2nd US patent granted on therapeutic antibodies for Parkinson s disease771
  Mar 19, 2015: Prothena Reports Robust Reduction of Free Serum Alpha-Synuclein of up to 96% After Single Dose of PRX002, a Novel Protein Immunotherapy for Parkinson's Disease772
  Mar 16, 2015: NeuroPhage to Present at 12th International Conference on Alzheimer s &Parkinson s Diseases791
  Dec 09, 2014: Parkinson's Vaccine: EU-Team Launches Clinical Trial Vaccine candidate based on proprietary technology by AFFiRiS791
  Nov 14, 2014: NeuroPhage s GAIM Technology Chosen As Top Project To Watch For The Therapeutic Area Partnerships Conference801
  Aug 26, 2014: Prothena Announces Presentation at Federation of European Physiological Societies 2014 Congress801
  Jul 31, 2014: First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development812
Appendix832
  Methodology831
  Coverage831
  Secondary Research831
  Primary Research831
  Expert Panel Validation831
  Contact Us831
  Disclaimer841

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016" Jun 30, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alpha-Synuclein-alphaSyn-or-SNCA-Pipeline-Review-H1-2016-2088-16129>
  
APA:
Global Markets Direct - Market Research. (2016). Alpha-Synuclein (alphaSyn or SNCA) - Pipeline Review, H1 2016 Jun 30, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Alpha-Synuclein-alphaSyn-or-SNCA-Pipeline-Review-H1-2016-2088-16129>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.